18:09 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Akcea's AKCEA-APO(a)-LRx reduces LPA levels in Phase II

Akcea Therapeutics Inc. (NASDAQ:AKCA) said AKCEA-APO(a)-LRx led to significant dose-dependent reductions in lipoprotein(a) (LPA) compared with placebo in a Phase II trial to reduce elevated LPA levels in patients with established cardiovascular disease. The company...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
03:13 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Amgen's Repatha lowers LDL-C in Phase III for dyslipidemia in Type II diabetics

Amgen Inc. (NASDAQ:AMGN) reported in June that Repatha evolocumab met the co-primary endpoints in the Phase III BANTING trial to treat hypercholesterolemia or mixed dyslipidemia in Type II diabetics taking the maximum tolerated dose of...
16:10 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Madrigal reports Phase II data of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) reported Phase II data for MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH) that, despite meeting the primary endpoint, suggest the candidate would be unable to compete with marketed drugs in...
21:13 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Athera begins Phase IIa trial of PC-mAb for arterial inflammation

Athera Biotechnologies AB (Stockholm, Sweden) began a Phase IIa trial of once-monthly IV PC-mAb to treat arterial inflammation in patients with elevated levels of lipoprotein(a) (LPA) . The double-blind, placebo-controlled, European trial's primary endpoint is...
19:54 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Madrigal completes enrollment in Phase II of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said it has enrolled 113 patients in a Phase II trial of MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH), exceeding its target enrollment of 105. The company said it would...
22:54 , Sep 14, 2017 |  BC Innovations  |  Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
19:07 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Regeneron reports Phase II data for evinacumab in HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from an open-label, international Phase II trial in 9 patients with homozygous familial hypercholesterolemia (HoFH) showing that evinacumab (REGN1500) added to current lipid-lowering therapy reduced mean LDL-C from baseline...
21:06 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

AKCEA-APO(a)-LRx: Ph IIb started

Ionis’ Akcea Therapeutics Inc. subsidiary began a double-blind, placebo-controlled, North American Phase IIb trial to evaluate 5 dose levels of subcutaneous AKCEA-APO(a)-LRx in about 270 patients with hyperlipoproteinemia(a) and established cardiovascular disease. In January, Ionis...
18:33 , Mar 31, 2017 |  BC Week In Review  |  Company News

Ionis to spin out lipid company Akcea

Ionis plans to spin out subsidiary Akcea Therapeutics Inc. in an IPO in which it would raise up to $100 million. Concurrently, partner Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) will invest $50 million in Akcea...